ELISpot in Cancer


ELISpot technique serves as an useful tool for testing cancer vaccine efficacy, detecting cancer biomarkers, and discriminating potential cancer symptoms. As cancer being the most dangerous disease, scientists never give up looking for specific and selective tumor antigens (often of viral origin) to apply in tumor-specific cancer vaccines.

Cancer Biomarkers (listed by cancer.gov)

Where are we now in Cancer Research?

Vaccination against cancer testis antigen (Sp17 in an OC mouse model) significantly controlled tumor growth.[1] The magnitude of antigen-specific IFN-γ-secreting cells, as measured by ELISpot, trended towards survival after the administration of a prostate-specific antigen vaccine in prostate cancer patients.[2] In ELISpot assays Targeting SHP2 against HNC cells could enhance T-cell-based cancer immunotherapy.[3] Addition of IFN-α significantly improved the frequency of p53-specific T cells in IFN-γ ELISpot assay.[4] In breast cancer, the release of cytokeratin-19 (CK19) and mucin-1 (MUC1) in single epithelial cancer cells are measured using ELISpot demonstrating that many patients harbored viable disseminated tumor cells, even in patients with apparently localized tumors.[5] Tumor specific effector T cells were detected in most patients with prostate cancer, especially those with castration resistant prostate cancer. Since effector T-cell responses against prostate specific antigens strongly increased after regulatory T-cell depletion, our results indicate that immunotherapy efficacy could be enhanced by decreasing regulatory T cells.[6]

ELISpot (Cancer) Reference:

[1] Chiriva IM, et al., Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer, PLoS One, 2010, 5(5):e10471;

[2] Gulley JL, et al., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer, Cancer Immunol Immunother. 2010, 59(5):663-674;

[3] Leibowitz MS, etal., SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells, Clin Cancer Res. 2013, 19(4):798-808;

[4] Zeestraten EC, et al., Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial, Int J Cancer, 2013, 132(7):1581-1591;

[5] Alix-Panabières C, EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients, Recent Results Cancer Res. 2012, 195:69-76.

[6] Hadaschik B, et al., Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer, J Urol, 2012, 187(4):1458-1465.

 

Featured ELISA Products:     Primary Antibodies (ELISA)          ELISA Kits